NCT00486564View on ClinicalTrials.gov

Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

June 30, 2009

Conditions
Neuroblastoma
Interventions
DRUG

Nifurtimox

Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.

Trial Locations (2)

63104

St. Louis University/Cardinal Glennon Childrens Medical Center, St Louis

05401

University of Vermont/Vermont Children's Hospital, Burlington

All Listed Sponsors
collaborator

St. Louis University

OTHER

lead

University of Vermont

OTHER

NCT00486564 - Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma | Biotech Hunter | Biotech Hunter